EP2015782A4 - Compositions and methods for modulating gene expression - Google Patents

Compositions and methods for modulating gene expression

Info

Publication number
EP2015782A4
EP2015782A4 EP07760600A EP07760600A EP2015782A4 EP 2015782 A4 EP2015782 A4 EP 2015782A4 EP 07760600 A EP07760600 A EP 07760600A EP 07760600 A EP07760600 A EP 07760600A EP 2015782 A4 EP2015782 A4 EP 2015782A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
gene expression
modulating gene
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07760600A
Other languages
German (de)
French (fr)
Other versions
EP2015782A2 (en
Inventor
Dusan Stanojevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crosslink Genetics Corp
Original Assignee
Crosslink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crosslink Genetics Corp filed Critical Crosslink Genetics Corp
Publication of EP2015782A2 publication Critical patent/EP2015782A2/en
Publication of EP2015782A4 publication Critical patent/EP2015782A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
EP07760600A 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression Withdrawn EP2015782A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130506P 2006-04-12 2006-04-12
PCT/US2007/066571 WO2007121326A2 (en) 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression

Publications (2)

Publication Number Publication Date
EP2015782A2 EP2015782A2 (en) 2009-01-21
EP2015782A4 true EP2015782A4 (en) 2010-04-07

Family

ID=38610393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07760600A Withdrawn EP2015782A4 (en) 2006-04-12 2007-04-12 Compositions and methods for modulating gene expression

Country Status (3)

Country Link
EP (1) EP2015782A4 (en)
CA (1) CA2649114A1 (en)
WO (1) WO2007121326A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3192529T3 (en) * 2009-04-08 2020-08-24 Heinz Faulstich Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
EP2436398B1 (en) * 2010-09-30 2013-01-23 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkers
CA2875945A1 (en) 2012-06-07 2013-12-12 The Children's Hospital Of Philadelphia Controlled gene expression methods
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
JP6321687B2 (en) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Amatoxin derivatives
JP7062647B2 (en) 2016-06-17 2022-05-06 マジェンタ セラピューティクス インコーポレイテッド Compositions and Methods for Depleting CD117 + Cells
CN109125736B (en) * 2017-08-18 2022-01-04 四川百利药业有限责任公司 Non-natural amatoxin antibody conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105045A1 (en) * 2000-10-13 2003-06-05 Crosslink Genetics Corporation Artificial transcriptional factors and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANSARI A Z ET AL: "TOWARDS A MINIMAL MOTIF FOR ARTIFICIAL TRANSCRIPTIONAL ACTIVATORS", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 8, no. 6, 1 January 2001 (2001-01-01), pages 583 - 592, XP001031162, ISSN: 1074-5521 *
ARORA PARAMJIT S ET AL: "Design of artificial transcriptional activators with rigid poly-L-proline linkers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 44, 6 November 2002 (2002-11-06), pages 13067 - 13071, XP007911805, ISSN: 0002-7863 *
INGLES C J ET AL: "ALPHA AMANITIN RESISTANCE OF RNA POLYMERASE II IN MUTANT CHINESE HAMSTER OVARY CELL LINES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 251, no. 9, 1976, pages 2729 - 2734, XP007911801, ISSN: 0021-9258 *
KUZNETSOVA S ET AL: "Gene activation by triplex-forming oligonucleotide coupled to the activating domain of protein VP16", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 20, 15 October 1999 (1999-10-15), pages 3995 - 4000, XP002222219, ISSN: 0305-1048 *
KWON YOUNGJOO ET AL: "Small molecule transcription factor mimic", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 49, 15 December 2004 (2004-12-15), pages 15940 - 15941, XP007911804, ISSN: 0002-7863 *
STANOJEVIC D ET AL: "A highly potent artificial transcription factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 41, no. 23, 11 June 2002 (2002-06-11), pages 7209 - 7216, XP002222221, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
CA2649114A1 (en) 2007-10-25
WO2007121326A2 (en) 2007-10-25
WO2007121326A3 (en) 2008-12-24
EP2015782A2 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
ZA200908481B (en) Compositions and methods for altering gene expression
IL250678A0 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
EP2052085A4 (en) Methods for modulating set and uses thereof
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
IL194788A0 (en) Compositions and methods for modulating vascular development
EP2068875A4 (en) Compositions and methods for modulating sirtuin activity
EP2043696A4 (en) Methods and compositions for targeting gc1qr/p32
IL202184A0 (en) Methods and compositions for increased transgene expression
EP2066687A4 (en) Compositions and methods for inhibiting expression of the hamp gene
IL194814A0 (en) Mglur5 modulators i
EP2129680A4 (en) Combined hairpin-antisense compositions and methods for modulating expression
EP2101731A4 (en) Endoxifen methods and compositions
ZA200807714B (en) Gene disruptions, compositions and methods relating thereto
EP2235033A4 (en) Methods and compositions for increasing gene expression
EP2088865A4 (en) Guggulphospholipid methods and compositions
AU2007291030A8 (en) Novel compositions and methods
ZA200808498B (en) Novel gene disruptions,compositions and methods relating thereto
EP2015782A4 (en) Compositions and methods for modulating gene expression
EP2018443A4 (en) Compositions and methods for inhibiting expression of ikk-b gene
GB0610009D0 (en) Culture medium
EP2142672A4 (en) Compositions and methods for gene silencing
PL2132251T3 (en) Composition and method
GB0625208D0 (en) Composition and method
GB0600261D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081112

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20081224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/00 20060101ALI20090120BHEP

Ipc: A61K 38/00 20060101ALI20090120BHEP

Ipc: C12Q 1/02 20060101ALI20090120BHEP

Ipc: C12Q 1/68 20060101AFI20090120BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100304

17Q First examination report despatched

Effective date: 20100616

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CROSSLINK GENETICS CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140325

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140805